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treated with statins tend to present less (44%) asymptomatic PAD than other patients 
(OR 0.56; 95%CI 0.30–1.05;p  0.07). Seventy-four percent of patients were 
aware of their CV risk, and smoking, high cholesterol, overweight and hypertension 
were identiﬁed by patients as the most important factors increasing the risk on 
CV disease. CONCLUSIONS: Asymptomatic PAD in subjects without CVD but 
at moderate risk was less prevalent in Belgium than in the other European countries, 
but was still signiﬁcantly correlated with classical CVD risk factors, especially 
smoking, hypertension, lipid proﬁle and age. It could be advisable to identify patients 
with such risk factors through ABI measurement and treat them accordingly as high 
risk individuals.
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OBJECTIVES: To compare 5-year cardiovascular (CV) event reduction between 
patients treated with generic simvastatin therapy (ST) and niacin extended-release 
[NER]  simvastatin (NER/S) combination therapy among primary and secondary risk 
patients from a managed care organization’s perspective. METHODS: Two hypotheti-
cal managed care formularies, each consisting of 1,000,000 primary and secondary 
risk patients were modeled over a ﬁve year time horizon: a current formulary where 
all patients were treated with ST and a revised formulary where all the patients were 
treated with NER/S. Study patients with sub-optimal LDL-C, HDL-C, and/or TG at 
baseline were sampled from the HealthCore Integrated Research Database between 
January 1, 2000 and February 28, 2005. Package insert efﬁcacy of lipid medications 
in each formulary was applied to the study population. Post-treatment lipid values 
were evaluated according to U.S. lipid guidelines. Incremental reduction in CV events 
[myocardial infarction (MI), peripheral vascular disease (PVD), and stroke] among 
NER/S treated patients versus ST patients was estimated. Market share of NER/S over 
ﬁve years was assumed to be 1.5%. RESULTS: A total of 529,620 study patients were 
identiﬁed, having a mean age of 54 o 11 years, 45% female, and Deyo-Chrlson 
comorbidity score of 0.38 o 0.62. Patients treated with NER/S therapy demonstrated 
an incremental reduction of 1,515 CV events (27,218 vs. 28,733) over 5 years as 
compared to ST. Incremental reduction in stroke events in the same period were 
found to be 564 (10,144 vs. 10,708), MI events reduced by 631 (11,341 vs. 11,972), 
while PVD events reduced by 319 (5,733 vs. 6,052). CONCLUSIONS: Treatment 
with NER/S among primary and secondary risk dyslipidemia patients was associated 
with 5-year reductions in CV events compared to ST treated patients. Further studies 
assessing the addition of NER to ST or switching ST treated patients to NER/S therapy 
on clinical and economic outcomes are needed.
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OBJECTIVES: There is little evidence to compare effectiveness of individual 
Angiotensin Receptor Blockers (ARBs) in patients with chronic heart failure (CHF). 
This study compared four ARBs in reducing risk of mortality in everyday clinical 
practice. METHODS: A retrospective analysis was conducted on a national sample 
of patients diagnosed with CHF from October 1, 1996 to September 30, 2002 
identiﬁed from VA Electronic Medical Records, with supplemental clinical data 
obtained from chart review. After excluding patients with exposure to ARBs 
within the previous six months, four treatment groups were deﬁned based on 
initial use of candesartan, valsartan, losartan, and irbesartan between the index 
date (October 1, 2000) and the study end date (September 30, 2002). Time to death 
was measured concurrently during that period. A marginal structural model (MSM) 
controlled for sociodemographic factors, comorbidities, co medications, disease 
severity (left ventricular ejection fraction), and potential time-varying confounding 
affected by previous treatment (hospitalization). Propensity scores derived from a 
multinomial logistic regression were used as inverse probability of treatment weights 
(IPTW) in a generalized estimating equation to estimate causal effects. Results of MSM 
were compared to estimates obtained from traditional Cox regression models 
RESULTS: Among the 1,536 patients identiﬁed on ARB therapy, irbesartan was 
most frequently used (55.21%), followed by losartan (21.74%), candesartan(15.23%) 
and valsartan (7.81%). Adjusted hazard ratios from Cox regression found Candesar-
tan to reduce risk of mortality compared with Losartan (HR  0.60, 95% CI 0.37–
0.96). After adjusting for time-varying hospitalization in MSM utilizing IPTW, 
candesartan was found not signiﬁcant (OR  0.79, 95% CI  0.42–1.50). Irbesartan 
and valsartan were found to have similar effectiveness compared to losartan in both 
analyses. CONCLUSIONS: Effectiveness of ARBs in reducing mortality did not differ 
in patients with CHF in everyday clinical practice. Marginal structural models can be 
used to compare the effectiveness of multiple treatment groups and may improve 
risk-adjustment.
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OBJECTIVES: Statin therapy has established cardiovascular beneﬁts. Clinical guide-
lines set target cholesterol levels for populations at different risk levels. Treatment 
strategies include initial high-dose or conventional-dose statin followed by titration of 
patients failing to reach target. Empirical data on dose titration are scarce, but this 
model simulates potential cholesterol reductions for different populations, therapies 
and titration steps. METHODS: Patient-level cholesterol values before statin therapy, 
obtained from a large UK primary care database, were grouped into four patient 
groups in 0.5 mmol/L bands from  1–10: 1) no CVD or diabetes; 2) CVD, no dia-
betes; 3) diabetes, no CVD; 4) diabetes and CVD. Dose efﬁcacy studies enabled cal-
culation of percentage reductions in cholesterol from speciﬁed therapies in each band, 
variance, and the corresponding probability of reaching a speciﬁed target. For patients 
failing to reach target, the next higher statin dose was applied to the starting choles-
terol value. Mean cholesterol values of those above/below target were calculated and 
inserted into a lifetime, cardiovascular outcomes, Excel-based model using Framing-
ham risk equations and baseline parameters from statin clinical trials. RESULTS: For 
the 4 population groups, with a mean cholesterol reduction of 30% (SD 10%), propor-
tions reaching a 4 mmol/L target in one step were: 1) 24%; 2) 35%; 3) 40%; and 4) 
45%. Patients above target had two further titrations, each higher-dose therapy reduc-
ing cholesterol by a further 5%, with proportions increasing to 49%, 63%, 68% and 
71% respectively. Based on these proportions and using Framingham risk equations, 
corresponding 10-year CVD event rates were estimated as 27%, 42%, 29% and 55% 
for one-step therapy, and 23%, 39%, 26% and 52% following titration. CONCLU-
SIONS: Titration models provide insights about the impact of different therapy strate-
gies on cardiovascular outcomes for different population groups. The addition of cost 
data enables the cost-effectiveness of competing statin strategies to be estimated.
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OBJECTIVES: To analyze the percentage of patients treated with anti-hypertensive 
medication in mono or dual therapy that experienced a CV event. METHODS: A 
retrospective study of the Southwestern Ontario database which contains chart-
abstracted information from primary health care facilities in Ontario, Canada was 
performed. Patients with hypertension were identiﬁed as those with a recorded Blood 
Pressure (BP) exceeding 140/90 mmHg, chart entry of a diagnosis of hypertension, or 
use of anti-hypertensive medication. Patients treated either in mono or dual therapy 
with angiotensin II receptor blockers (ARBs), ACE Inhibitors (ACEIs) and Calcium 
Channel Blockers (CCBs) were included. The number of patients who experienced at 
least one CV event from 2003 to 2008 was recorded. CV events are stroke, myocardial 
infarction, congestive heart failure, peripheral vascular disease, coronary heart disease, 
atrial ﬁbrillation or transient cerebral ischemic attack. Due to the well known com-
parable safety proﬁle of the compounds, a safety analysis was not performed. 
RESULTS: A total of 53,064 patients treated with an ARB, ACEI or CCB in mono 
or dual therapy were identiﬁed. The proportions of treated patients who experienced 
a CV event were 4.3% on ARBs compared to 7.0% on ACEIs and 11.0% on CCBs. 
These differences were statistically signiﬁcant (p  0.001). Within the ARB class, the 
proportions of treated patients who experienced a CV event were 3.0% on irbesartan 
compared to 4.6% on losartan, 5.0% on valsartan and 5.0% on candesartan. These 
differences were statistically signiﬁcant (p  0.02). CONCLUSIONS: In patients 
treated in mono or dual therapy, those treated with an ARB experienced signiﬁcantly 
fewer CV events than those treated with an ACEI or a CCB. Amongst the ARB-treated 
patients, those treated with irbesartan as part of their therapy experienced signiﬁcantly 
less CV events than those treated with another ARB.
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OBJECTIVES: To compare the effectiveness of the most commonly prescribed statins 
in Brazil for the prevention of cardiovascular CV events, using indirect comparison 
meta-analysis. METHODS: A systematic review of the literature was conducted. 
Medline and the Cochrane Controlled Trials Register were searched for clinical 
trials that compared Pravastatin 40 mg, Simvastatin 40 mg or Atorvastatin 10 mg 
against control (placebo or usual care), for primary and secondary CV prevention. 
Full-texts of relevant abstracts were retrieved and evaluated in duplicate and indepen-
dently. Fixed-effect models were used for direct statin versus control comparisons, 
and the methodology described by Bucher et al. (1997) was used to derive indirect 
comparisons between statins. RESULTS: Eleven studies comparing Pravastatin 40 mg 
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(n  39,530), three comparing Simvastatin (n  20,859) and three comparing Atorv-
astatin (n  15,553) versus control were retrieved. No head-to-head comparisons 
between these statins in the pre-deﬁned doses were found. All statins were signiﬁcantly 
superior to control in the evaluated outcomes, and the highest risk reductions observed 
were for non-fatal myocardial infarction (MI): Atorvastatin relative risk (RR)  0.57 
(95% CI: 0.44–0.74, I2  0%), Pravastatin RR  0.79 (95% CI: 0.73–0.86, I2  12%), 
 Simvastatin RR  0.62 (95% CI: 0.54–0.70, I2  0%). Indirect comparisons showed 
no statistically signiﬁcant difference between statins in the prevention of total death, 
CV death and stroke. When compared to Pravastatin, the RR of MI for Simvastatin 
was 0.78 (95% CI: 0.67–0.91) and for Atorvastatin was 0.71 (95% CI: 0.54–0.94); 
the comparison between Atorvastatin versus Simvastatin showed no difference (RR  
0.92, 95% CI: 0.68–1.29). CONCLUSIONS: Our results showed similar efﬁcacy 
among these statins in major events reduction in the doses evaluated. Pravastatin seems 
to be less effective than the others in the prevention of MIs. Considering the similar 
results of these drugs, market price must be used in the selection of the most appropri-
ate therapy.
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OBJECTIVES: This study compared blood pressure (BP) outcomes (changes in BP and 
goal attainment) in adult patients (age 18 years) treated with an ARB or ARB-HCTZ 
ﬁxed dose combination. METHODS: A retrospective study was conducted using the 
GE Centricity EMR database, which contains the ambulatory health records for more 
than 11 million US patients. Patients with a physician order for one of the following 
ARBs or ﬁxed-dose combination (FDC) with HCTZ (candesartan, irbesartan, losar-
tan, olmesartan or valsartan) prior to December 2007 were included in the study. 
Demographics, clinical characteristics (co-morbidities, previous antihypertensive medi-
cations) and BP readings at baseline and throughout the 13-month follow-up period 
were recorded. The mean change in systolic and diastolic BPs and percent patients 
attaining BP goal (two consecutive BP readings 140/90 or 130/80 in patients with 
diabetes or renal disease) were recorded. RESULTS: A total of 81,706 patients (60.5% 
female, mean age 61.6 years) receiving an ARB or ARB-HCTZ FDC were identiﬁed. 
Patients with prior antihypertensive medication usage [57,501 (70.4%)] had higher 
baseline BP readings [mean SBP (SD): 147.4 (29.35) vs. 138.7 (18.93) mmHg; mean 
DBP (SD): 84.2 (17.93) vs. 80.8 (12.35)] and also experienced greater reductions in 
BP [mean SBP change (SD): 21.1 (29.61) vs. 13.2 (17.31) mmHg]. At baseline, a 
greater proportion of patients with prior antihypertensive medication usage (57.8% 
vs. 49.5) were not at BP goal. BP goal attainment was similar between the two groups 
(60.6% vs. 62.6%, prior vs. absence, respectively). Mean time to goal (82.8 days vs. 
78.5 days, prior vs. absence, respectively) was also similar between the two groups. 
CONCLUSIONS: Most patients initiating ARB /ARB-HCTZ therapy have utilized 
other antihypertensive medications in the 13 months prior to starting ARBs. Prior 
antihypertensive medication users experienced greater reductions in BP. BP goal 
 attainment was similar between patients with and without prior antihypertensive 
medications.
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OBJECTIVES: Compare combined optimal lipid value (OLV) goal attainment [low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
C), and triglycerides (TG)] between patients initiating niacin extended-release [NER] 
 simvastatin (NER/S) and ezetimibe  simvastatin (E/S) combination therapies among 
patients in a managed care setting. METHODS: An observational cohort study of 
patients aged  18 initiating NER/S (addition of NER to existing simvastatin therapy) 
or E/S therapy between January 1, 2001 and June 30, 2006 (index date) was performed 
using the HealthCore Integrated Research Database. Patients with a minimum 24 
months of follow-up and diagnosis of cardiovascular disease during the 12 months 
prior to index date were included. A propensity score regression model for treatment 
selection was created after adjusting for age, gender, baseline LDL-C, HDL-C, and 
TG, and Deyo-Charlson comorbidity index (DCI) score. The propensity score was 
included in a multivariate logistic regression model to estimate combined OLV goal 
attainment (per treatment guidelines) between the groups. RESULTS: A total of 883 
patients were identiﬁed initiating NER/S (n  445) or E/S (n  438). E/S patients were 
younger (51.4 o 8.4 years vs. 54.0 o 8.5 years; p  0.001) and less likely to be male 
(55.3% vs. 81.1%; p  0.001). Fewer E/S patients were likely to have prior hyperten-
sion (67.1% vs. 80.2%; p  0.001) and congestive heart disease (17.1% vs. 45.6%; 
p  0.001) versus NER/S patients, though the pre-index DCI score was statistically 
non-signiﬁcant between the groups (0.7 o 1.1: E/S vs. 0.8 o 1.1: NER/S; p  0.097). 
Logistic regression showed that NER/S patients were 64% more likely to achieve 
combined OLV goal attainment as compared to E/S treated patients [Odds Ratio: 1.64 
(95% CI: 1.02—2.62); p  0.04]. CONCLUSIONS: NER/S treatment was associated 
with a likelihood of combined OLV goal attainment versus E/S patients. Further 
research on impact of early initiation of NER/S therapy emphasizing multiple lipid 
parameter management versus LDL-C-only focused treatment strategies comes is 
warranted.
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OBJECTIVES: 1) To compare antihypertensive efﬁcacy of Losartan and Irbesartan 
controlling for baseline Seated Diastolic and Systolic Blood Pressure (SeDBP&SeSBP) 
before treatments, and 2) to compare antihypertensive efﬁcacy of Losartan and 
 Irbesartan between gender controlling for 1) baseline SeDBP&SeSBP, and 2) age. 
METHODS: An experimental design was performed. All hypertensive patients who 
were prescribed 50 mg. Losartan once a day or 150 mg. Irbesartan once a day for 
hypertension during January 1-June 30, 2008 were the population framework. Exclu-
sion criteria included concomitant diseases that would present safety hazards and 
concomitant medications that might interfere with the assessment of efﬁcacy or safety 
e.g., drugs known to affect BP. Simple random technique was employed. The A 0.05, 
power 0.90 and effect size 0.07 were set to generate 200 samples in each group (total 
400). The average baseline SeDBP&SeSBP of Losartan group and Irbesartan group 
were 91.86 o 13.73, 150.76 o 19.14 and 89.56 o 10.69, 148.42 o 15.45 respectively. 
Baseline SeDBP&SeSBP were used as covariates. After medications for eight weeks 
SeDBP&SeSBP were measured and compared. RESULTS: Total 400 (100%) patients, 
mostly 267 (66.80%) were female, 133 (33.33%) were male with average age 63.31 
o 12.52 years. After treatment the average SeDBP of Losartan or Irbesartan groups 
were 77.26 o 9.76 and 74.43 o 9.84 mm. Hg respectively (p  .000, ANCOVA). After 
treatment the average SeSBP of Losartan or Irbesartan groups were 131.72 o 15.17 
and 127.50 o 12.22 mm. Hg respectively (p  .010, ANCOVA). When controlled age 
(covariate) and added gender (ﬁxed factor) to the model, the means of SeDBP&SeSBP 
of Losartan group and Irbesartan group were 77.26 o 9.76, 128.81 o 12.89 and 72.43 
o 9.84, 127.50 o 12.22 mm. Hg respectively (p  0.000 and 0.029, two way ANCOVA 
without gender interaction (p  0.520, 0.101). CONCLUSIONS: Irbesartan 150 mg. 
once a day could signiﬁcantly lower seated systolic and diastolic blood pressure in 
hypertension patients better than Losartan 50 mg. once a day. Gender made no dif-
ferences on efﬁcacy of the two drugs.
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OBJECTIVES: To compare the effectiveness of dual combinations of angiotensin II 
receptor blockers (ARBs) and ACE Inhibitors (ACEIs) with hydrochlorothiazide 
(HCTZ) or Calcium Channel Blockers (CCBs) in reaching target blood pressure (BP) 
in a real-world setting. METHODS: Records from a longitudinal population-based 
database of more than 170,000 patients in over 53 family practice clinics in south-
western Ontario, Canada were analyzed. These records contained chart-abstracted 
information such as visit diagnosis, BP, medications and consultation notes. The 
records from adult non-diabetic patients who were diagnosed with hypertension and 
were initiated on the combination therapy in 2005 and continued on the combination 
for at least 9 months were included. Hypertension was deﬁned as a BP exceeding 
140/90 mmHg, chart entry of a diagnosis of hypertension, or use of anti-hypertensive 
medication. The proportions of patients reaching target BP (BP less than 140/90 mmHg) 
were recorded and the combination of ARBsHCTZ was compared to other combina-
tions. Due to the well known comparable safety proﬁle of the compounds, a safety 
analysis was not performed. RESULTS: A total of 4,458 patients were treated with 
dual combinations of ARBs and ACEIs with HCTZ or CCBs. The proportions of 
patients reaching target BP were 35% on ARBs  HCTZ compared to 30% on 
ACEIsHCTZ (p  0.006), 32% on ARBsCCBs (p  0.03), and 28% on ACEIsCCBs 
(p  0.001). CONCLUSIONS: In the real-world setting, a greater proportion of 
hypertensive patients treated with the dual combination ARBHCTZ reached target 
BP than the dual combinations of ARBCCB, ACEIHCTZ, or ACECCB. Patients 
treated with the combination of an ARB with HCTZ or CCB achieved target BP in a 
greater proportion than patients treated with ACEI-based counterparts.
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BACKGROUND: The randomized double-blind parallel group trial, INPRACTICE, 
demonstrated a signiﬁcant beneﬁt of ezetimibe co-administration with simvastain 
10/40 mg in patients achieving LDL-C targets of 2 mmol/L, compared to atorvastatin 
